{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:07:19Z","timestamp":1782263239863,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.82373724"],"award-info":[{"award-number":["No.82373724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Fund of Henan Provincial Science and Technology Research and Development Plan","award":["No.242301420074"],"award-info":[{"award-number":["No.242301420074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The tumor vasculature exhibits immature development characterized by inadequate pericyte coverage, resulting in excessive permeability, poor perfusion, and hypoxia. The aberrant vascular network not only facilitates metastasis but also confers therapeutic resistance. Accumulating evidence indicates that inducing tumor vascular normalization represents a promising antitumor strategy. Given the pivotal role of the APLN\/APLNR axis in vascular maturation positions it as a promising therapeutic target for anti-tumor vascular therapy.This study aims to discover novel APLNR antagonists, investigate their effects on tumor vascular normalization, and evaluate their combinatorial efficacy with existing anticancer therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Initially, based on a drug repurposing strategy, we employed computer-aided virtual screening to identify compounds with high binding affinity to APLNR from the FDA-approved drug library. And further utilized a zebrafish retinal vascular abnormality model to screen out the candidate compound that could induce vascular normalization. Then, we assessed the impact of the candidate compound on vascular normalization by detecting the proliferation, migration and tubule formation abilities of HUVEC in vitro and investigating tumor vascular maturity, vascular perfusion and hypoxia in vivo. Additionally, we explored the molecular mechanisms underlying the regulation of vascular normalization by the candidate compound using western blot and comet assay. Finally, we employed a breast cancer mouse model to examine the antitumor efficacy of the candidate compound when used alone or in combination with Sunitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Employing a drug repurposing strategy combined with computational screening, we identified Candesartan, an approved antihypertensive drug with a well-established safety profile, as a high-affinity APLNR antagonist. Additionally, in vitro, Candesartan significantly inhibited HUVEC proliferation, migration, and tube formation. In vivo, it promoted tumor vascular maturation, improved vascular perfusion, and alleviated hypoxia. Mechanistically, Candesartan activated the ROS\/dsDNA\/cGAS\/STING pathway to drive vascular normalization. Notably, Candesartan synergistically potentiated sunitinib\u2019s antitumor efficacy while inhibiting pulmonary metastasis and ameliorating Sunitinib-induced hepatotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a novel direction for APLNR antagonist development and demonstrates that combining Candesartan with the standard antiangiogenic agent Sunitinib leverages the advantage of drug repurposing, suggesting a promising and rapidly translatable strategy for optimized cancer therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03584-4","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:03:55Z","timestamp":1764324235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS\/cGAS\/STING axis and augmented sunitinib response in breast cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Chenyu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"1","key":"3584_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","volume":"13","author":"X Liu","year":"2025","unstructured":"Liu X, Zhang J, Yi T, Li H, Tang X, Liu D, et al. Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies. Biomark Res. 2025;13(1):62.","journal-title":"Biomark Res"},{"issue":"15","key":"3584_CR2","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.7150\/thno.84947","volume":"13","author":"Q Lin","year":"2023","unstructured":"Lin Q, Choyke PL, Sato N. Visualizing vasculature and its response to therapy in the tumor microenvironment. Theranostics. 2023;13(15):5223\u201346.","journal-title":"Theranostics"},{"issue":"2","key":"3584_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.clgc.2016.10.004","volume":"15","author":"P Ivanyi","year":"2017","unstructured":"Ivanyi P, Beutel G, Drewes N, Pirr J, Kielstein JT, Morgan M, et al. Therapy of Treatment-Related hypertension in metastatic Renal-Cell cancer patients receiving Sunitinib. Clin Genitourin Cancer. 2017;15(2):280\u2013e903.","journal-title":"Clin Genitourin Cancer"},{"issue":"17","key":"3584_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/CM9.0000000000003231","volume":"137","author":"Z Guo","year":"2024","unstructured":"Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y. Tumor angiogenesis and anti-angiogenic therapy. Chin Med J (Engl). 2024;137(17):2043\u201351.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"3584_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10555-025-10267-1","volume":"44","author":"NA Tran","year":"2025","unstructured":"Tran NA, Moonshi SS, Lam AK, Lu CT, Vu CQ, Arai S, et al. Nanomaterials in cancer starvation therapy: pioneering advances, therapeutic potential, and clinical challenges. Cancer Metastasis Rev. 2025;44(2):51.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"3584_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40265-014-0243-3","volume":"74","author":"PL McCormack","year":"2014","unstructured":"McCormack PL. Pazopanib: a review of its use in the management of advanced renal cell carcinoma. Drugs. 2014;74(10):1111\u201325.","journal-title":"Drugs"},{"issue":"9","key":"3584_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987\u20139.","journal-title":"Nat Med"},{"issue":"11","key":"3584_CR8","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","volume":"55","author":"Y Choi","year":"2023","unstructured":"Choi Y, Jung K. Normalization of the tumor microenvironment by Harnessing vascular and immune modulation to achieve enhanced cancer therapy. Exp Mol Med. 2023;55(11):2308\u201319.","journal-title":"Exp Mol Med"},{"key":"3584_CR9","doi-asserted-by":"crossref","unstructured":"Fon\u00f3di M, Nagy L, Boratk\u00f3 A. Role of protein phosphatases in tumor angiogenesis: assessing PP1, PP2A, PP2B and PTPs activity. Int J Mol Sci. 2024;25(13):6868.","DOI":"10.3390\/ijms25136868"},{"issue":"1","key":"3584_CR10","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1038\/s41467-024-50540-5","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Song J, Jeong HW, Gr\u00f6nloh MLB, Koh BI, Bovay E, et al. Apelin modulates inflammation and leukocyte recruitment in experimental autoimmune encephalomyelitis. Nat Commun. 2024;15(1):6282.","journal-title":"Nat Commun"},{"issue":"7","key":"3584_CR11","doi-asserted-by":"publisher","first-page":"104589","DOI":"10.1016\/j.isci.2022.104589","volume":"25","author":"U Lee","year":"2022","unstructured":"Lee U, Stuelsatz P, Karaz S, McKellar DW, Russeil J, Deak M, et al. A Tead1-Apelin axis directs paracrine communication from myogenic to endothelial cells in skeletal muscle. iScience. 2022;25(7):104589.","journal-title":"iScience"},{"issue":"7","key":"3584_CR12","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.3390\/ijms26072986","volume":"26","author":"L Naldi","year":"2025","unstructured":"Naldi L, Peri A, Fibbi B. Apelin\/APJ: another player in the cancer biology network. Int J Mol Sci. 2025;26(7):3801.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3584_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/pharmaceutics15051408","volume":"15","author":"D Rossin","year":"2023","unstructured":"Rossin D, Vanni R, Lo Iacono M, Cristallini C, Giachino C, Rastaldo R. APJ as promising therapeutic target of peptide analogues in myocardial Infarction- and Hypertension-Induced heart failure. Pharmaceutics. 2023;15(5):1333.","journal-title":"Pharmaceutics"},{"issue":"10","key":"3584_CR14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/jpm11100976","volume":"11","author":"AS Wahba","year":"2021","unstructured":"Wahba AS, Ibrahim ME, Abo-Elmatty DM, Mehanna ET. Association of the adipokines Chemerin, Apelin, Vaspin and omentin and their functional genetic variants with rheumatoid arthritis. J Pers Med. 2021;11(10):986.","journal-title":"J Pers Med"},{"issue":"3","key":"3584_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s44321-025-00196-5","volume":"17","author":"B Demoures","year":"2025","unstructured":"Demoures B, Soulet F, Descarpentrie J, Galeano-Otero I, Sanchez Collado J, Casado M, et al. Repression of Apelin Furin cleavage sites provides antimetastatic strategy in colorectal cancer. EMBO Mol Med. 2025;17(3):504\u201334.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"3584_CR16","doi-asserted-by":"publisher","first-page":"10714","DOI":"10.1038\/s41467-024-55381-w","volume":"15","author":"TL Williams","year":"2024","unstructured":"Williams TL, Verdon G, Kuc RE, Currinn H, Bender B, Solcan N, et al. Structural and functional determination of peptide versus small molecule ligand binding at the Apelin receptor. Nat Commun. 2024;15(1):10714.","journal-title":"Nat Commun"},{"issue":"9","key":"3584_CR17","doi-asserted-by":"publisher","first-page":"e0202436","DOI":"10.1371\/journal.pone.0202436","volume":"13","author":"D McAnally","year":"2018","unstructured":"McAnally D, Siddiquee K, Gomaa A, Szabo A, Vasile S, Maloney PR, et al. Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS ONE. 2018;13(9):e0202436.","journal-title":"PLoS ONE"},{"issue":"3","key":"3584_CR18","doi-asserted-by":"publisher","first-page":"eaax7379","DOI":"10.1126\/sciadv.aax7379","volume":"6","author":"Y Ma","year":"2020","unstructured":"Ma Y, Ding Y, Song X, Ma X, Li X, Zhang N, et al. Structure-guided discovery of a single-domain antibody agonist against human Apelin receptor. Sci Adv. 2020;6(3):eaax7379.","journal-title":"Sci Adv"},{"issue":"3","key":"3584_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","volume":"26","author":"AC Dudley","year":"2023","unstructured":"Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023;26(3):313\u201347.","journal-title":"Angiogenesis"},{"key":"3584_CR20","doi-asserted-by":"publisher","first-page":"118129","DOI":"10.1016\/j.bmc.2025.118129","volume":"121","author":"Z Liu","year":"2025","unstructured":"Liu Z, Li T, Gu C, Chen C, Tang Z, Feng Y, et al. Novel agents derived from natural product \u03b2-elemene: A second round of design and synthesis to enhance antitumor properties. Bioorg Med Chem. 2025;121:118129.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"3584_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/cells14060407","volume":"14","author":"A Nowacka","year":"2025","unstructured":"Nowacka A, \u015aniegocki M, Smuczy\u0144ski W, Bo\u017ci\u0142ow D, Zi\u00f3\u0142kowska E. Angiogenesis in Glioblastoma-Treatment approaches. Cells. 2025;14(6):533.","journal-title":"Cells"},{"issue":"1","key":"3584_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","volume":"37","author":"DW Siemann","year":"2011","unstructured":"Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular disrupting agents. Cancer Treat Rev. 2011;37(1):63\u201374.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3584_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40364-021-00312-w","volume":"9","author":"W Chen","year":"2021","unstructured":"Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, et al. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res. 2021;9(1):59.","journal-title":"Biomark Res"},{"issue":"2","key":"3584_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/ph17020195","volume":"17","author":"RA Qannita","year":"2024","unstructured":"Qannita RA, Alalami AI, Harb AA, Aleidi SM, Taneera J, Abu-Gharbieh E, et al. Targeting Hypoxia-Inducible Factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals (Basel). 2024;17(2):244.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"3584_CR25","doi-asserted-by":"publisher","first-page":"e001844","DOI":"10.1136\/jitc-2020-001906","volume":"9","author":"M Chelvanambi","year":"2021","unstructured":"Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9(2):e001844.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3584_CR26","doi-asserted-by":"publisher","first-page":"2093054","DOI":"10.1080\/2162402X.2022.2093054","volume":"11","author":"T He","year":"2022","unstructured":"He T, Hao Z, Lin M, Xin Z, Chen Y, Ouyang W, et al. Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation. Oncoimmunology. 2022;11(1):2093054.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3584_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41467-023-43743-9","volume":"15","author":"H Lv","year":"2024","unstructured":"Lv H, Zong Q, Chen C, Lv G, Xiang W, Xing F, et al. TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer. Nat Commun. 2024;15(1):6.","journal-title":"Nat Commun"},{"key":"3584_CR28","doi-asserted-by":"publisher","first-page":"107063","DOI":"10.1016\/j.phrs.2024.107063","volume":"201","author":"X He","year":"2024","unstructured":"He X, Wedn A, Wang J, Gu Y, Liu H, Zhang J, et al. IUPHAR ECR review: the cGAS-STING pathway: novel functions beyond innate immune and emerging therapeutic opportunities. Pharmacol Res. 2024;201:107063.","journal-title":"Pharmacol Res"},{"issue":"6","key":"3584_CR29","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/hep.31545","volume":"73","author":"L Chen","year":"2021","unstructured":"Chen L, Zhou T, White T, O\u2019Brien A, Chakraborty S, Liangpunsakul S, et al. The Apelin-Apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis. Hepatology. 2021;73(6):2411\u201328.","journal-title":"Hepatology"},{"issue":"5","key":"3584_CR30","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2353\/ajpath.2007.070471","volume":"171","author":"T Hashimoto","year":"2007","unstructured":"Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol. 2007;171(5):1705\u201312.","journal-title":"Am J Pathol"},{"issue":"10","key":"3584_CR31","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1002\/jcp.26554","volume":"233","author":"M Liu","year":"2018","unstructured":"Liu M, Li H, Zhou Q, Zhao H, Lv D, Cao J, et al. ROS-Autophagy pathway mediates monocytes-human umbilical vein endothelial cells adhesion induced by apelin-13. J Cell Physiol. 2018;233(10):6839\u201350.","journal-title":"J Cell Physiol"},{"issue":"3","key":"3584_CR32","first-page":"1","volume":"21","author":"Z Pan","year":"2025","unstructured":"Pan Z, Zhu L, Wang X, Huangfu N, Su P, Yang F, et al. Excessive autophagic degradation of MYLK3 causes sunitinib-induced cardiotoxicity. Autophagy. 2025;21(3):1\u201320.","journal-title":"Autophagy"},{"issue":"3","key":"3584_CR33","doi-asserted-by":"publisher","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2(3):a006486.","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03584-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:05:09Z","timestamp":1781618709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3584"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03584-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7148907\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal testing is authorized by the Animal Ethics Committee of Zhengzhou University. We followed all the rules and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}